Navigation Links
CMC, Moffitt Partner to Study Cancer
Date:2/26/2008

CHARLOTTE, N.C., Feb. 26 /PRNewswire-USNewswire/ -- The Blumenthal Cancer Center at Carolinas Medical Center (CMC) in Charlotte is partnering with the Moffitt Cancer Center in a study that could lead to individualized treatments for specific types of cancer. CMC is the first hospital system outside Moffitt's home state of Florida to participate.

Over the next five years, CMC will enroll more than 2,300 patients in the study, which will involve collecting tissue samples, medical histories and clinical records. Participation in the study will enable Blumenthal Cancer Center patients to benefit from clinical trials and new treatments that may result from the research.

Cancers are often categorized by where they originate; for example, lung, breast, colon and prostate. However, the study, called Total Cancer Care, recognizes that there are more than 200 different types of cancer irrespective of where they first appear.

Each type has a specific molecular "fingerprint" made up of some 30,000 genes that could affect how it responds to different forms of treatment. By developing a data base of tissue samples from many cancer types, it may be possible to design individualized therapies that target the specific cancer, avoiding treatments that have little or no effect.

"The Total Cancer Care project is the kind of clinical research that physicians at Blumenthal Cancer Center are seeking for their patients," said Dr. Jeffrey Kneisl, medical director of Blumenthal Cancer Center and principal investigator for the Total Cancer Care study at CMC. "This is a thoughtfully conceived, methodically planned project that joins comprehensive cancer centers, cutting-edge research and patient-specific care."

Enrollment in the study is completely voluntary. If patients have cancer surgery, they will be asked to donate excess cancer tissues that would otherwise be discarded. If a biopsy is taken, researchers would like to obtain three to six additional samples for study.

Volunteers may be asked questions on a yearly basis about their medical history, diet and how they feel. If a new drug is developed that addresses their specific form of cancer, patients will be notified by researchers to see if they would be willing to participate in a clinical trial of that drug.

"Our vision is to integrate new technologies into the standard of care and improve outcomes of all cancer patients by partnering with outstanding health care institutions," said Dr. William Dalton, Moffitt President/CEO and Center Director. "We are also looking forward to collaborating with the physicians to increase access to new and improved therapies for cancer."

Located in Tampa, Florida, Moffitt Cancer Center (http://www.moffitt.org) is recognized by the National Cancer Institute as a Comprehensive Cancer Center for its excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 15 affiliates in Florida, one in Georgia, and two in Puerto Rico.

Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country's leading cancer centers, and is listed in U.S. News & World Report as one of "America's Best Hospitals" for cancer, as well as for ear, nose and throat. Moffitt's sole mission is to contribute to the prevention and cure of cancer.

The American College of Surgeons Commission on Cancer has designated CMC as an Accredited Network Cancer Program, one of just 26 hospital systems nationwide to achieve that level of accreditation.

Information on participating in the trial at CMC may be obtained by contacting Melanie Bamberg, program manager, at 704-355-6980 or Melanie.Bamberg@carolinashealthcare.org.


'/>"/>
SOURCE Carolinas Medical Center
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. SpineSmith Partners to Present at 3rd Annual Stem Cell Summit
2. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
3. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
4. iCAD Announces Partnership for Initiating Clinical Testing of Its Virtual Colonoscopy CAD Product
5. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
6. UNICEF Partners With Causes on Facebook to Launch Charity Gift Feature
7. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
8. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
9. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
10. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
11. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , Mar. 29, 2017 Research and Markets has ... at Proton Therapy Centers & Forecast" report to their offering. ... Proton Therapy Market in ... its market value in 2016. There are currently three proton therapy centers ... to treat more patients. In Italy , the first ...
(Date:3/29/2017)... 2017  Providence Medical Technology, Inc., an innovator ... two industry veterans to the commercial leadership team.  ... to lead Global Marketing, and Michael Scott ... and Mr. Scott have over 40 years of ... joins the company with over 22 years of ...
(Date:3/29/2017)... 2017  Glenmark Pharmaceuticals, a global pharmaceutical company, ... investigational fixed-dose combination of mometasone furoate (25 mcg) ... a nasal spray being studied for the treatment ... a recently completed Phase 3 trial assessing the ... versus mometasone, olopatadine or placebo. "We ...
Breaking Medicine Technology:
(Date:3/30/2017)... , ... March 30, 2017 , ... ... the live audio conference “ Preventing Hospital Readmissions Through Discharge Planning ” with ... at 1:00 pm ET. This conference discusses strategies to prevent readmissions in light ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... squash, announced it has enlisted New York City-based sports and entertainment marketing firm ... and procure sponsorship opportunities for the Professional Squash Association (PSA), which includes first-time ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sublime Naturals and its founder, Kathy Heshelow, ... Spice", it has been used for thousands of years. , "The West has caught ... of " Turmeric: How to Use it For Your Wellness. Overcome Inflammation, Enemy of ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based ... into the challenges employers face in trying to balance both short-term and long-term ... programs? Adding to the growing complexity, companies are finding that the short-term ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... Device Library for documenting and diagramming network and data center assets and audio-video ... NetZoom subscribers can request new equipment shapes for free and download shapes and ...
Breaking Medicine News(10 mins):